Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 7
What the Lilly and Hims GLP-1 deal means
Lilly and Hims announced a US access channel for branded obesity medicines, including Zepbound. It is a commercial deal, not a new trial.
When Medicaid GLP-1 coverage ended
A 2026 study found a steep fall in Medicaid-reimbursed GLP-1 dispensing after five states withdrew obesity coverage.
Semaglutide in HFpEF: CAMEO-SEMA MRI
A 49-person CAMEO-SEMA substudy found improved cardiac filling measures with semaglutide, without testing hospitalization or survival.
Semaglutide, Depression and Motivation
A post-hoc depression-trial analysis found a change in effort-based decisions, but no proven metabolic mediator or brain mechanism.
Semaglutide's Phase 3 evidence mapped
A 2026 review maps semaglutide Phase 3 trials across diabetes, obesity, cardiovascular and kidney outcomes without erasing trial limits.
Tirzepatide, Semaglutide and Gut Bacteria
A 36-person OMDOT-1 analysis found exploratory gut microbiome changes with tirzepatide and semaglutide, without proving a clinical benefit.
Ipamorelin status in Norway
Ipamorelin has no identified Norwegian or central EU authorisation. Here is the current status, postal-import rule, and what changed in 2026.
PT-141 personal imports into the UK
No ordinary consumer route was verified for importing PT-141 research vials. The documented UK route is licensed, notified and prescriber-led.
What PT-141 actually costs in the UK
Zero official UK PT-141 prices were found. Here is why a specials quote, a US Vyleesi price and a research-vendor listing are different numbers.
PT-141 UK status: what changed
No UK-authorised bremelanotide or Vyleesi product was identified. Here is the product-status boundary and the documented 12-month no-change finding.
Retatrutide personal imports into the UK
No ordinary consumer route was verified for importing Retatrutide. UK guidance requires licensed, notified and prescriber-led channels.
Retatrutide UK status: what changed
Retatrutide is not authorised in the UK. MHRA warnings and seizures intensified in 2026, but no UK retail product was approved.